CRISPR expert Caszyme announces new mRNA capabilities at BIO2024 to meet growing demand for tailored gene editing solutions
Lithuanian Pavilion Booth no 3935
Vilnius, May 29, 2024: Caszyme, a leading biotechnology company specializing in CRISPR gene editing solutions, announces at BIO2024 in San Diego the addition of early-stage mRNA synthesis, analysis, and optimization to its range of capabilities. This strategic development enables Caszyme to provide more comprehensive solutions to its growing number of biopharma partners who are looking to add mRNA-based therapies to their pipelines.
Caszyme CEO Dr Monika Paulė comments: “The demand for tailored gene editing solutions continues to grow. By adding these new capabilities to test and optimise partners’ mRNA to our existing deep expertise in CRISPR gene editing technology, Caszyme will be able to offer more extensive development, validation and optimization of early-stage therapeutic concepts. This advancement ensures high efficiency and precision in gene editing outcomes, fostering opportunities for deeper and more versatile partnerships.”
Caszyme was established in 2017 by Dr. Monika Paulė together with Dr. Giedrius Gasiūnas and Prof. Virginijus Šikšnys – a pioneer of CRISPR-Cas gene editing research. Over the last 7 years, Caszyme has rapidly advanced its excellence and capabilities as an expert enabling partner in CRISPR gene editing solutions, collaborating with multiple life science organizations aiming to enter the CRISPR field or expand their gene editing capabilities.
-ends-
About Caszyme
Caszyme is a leading biotechnology company specializing in CRISPR gene editing solutions, empowering partners with its deep expertise and highly flexible platform. Caszyme’s innovative approach enables the development of market-ready products for various application areas of CRISPR-Cas technology, including:
- Therapeutics & Diagnostics: offering precise and tailored solutions to treat and cure genetic and acquired diseases, becoming a key technology for development of personalized medicine.
- Agriculture & Food: providing answers to the pressing challenges facing agriculture, from sustainably improving productivity to providing an alternative to pesticides, increasing heat resistance and enhancing nutritional benefits.
- White & Blue Biotechnology: revolutionizing industrial biotechnology by enabling the efficient design and optimization of microorganisms for a wide range of applications.
- Discovery: enabling precise genetic manipulation that accelerates the exploration of fundamental biological processes and the development of novel scientific insights.
-ends-
For more information visit www.caszyme.com
Contact: Karolina Makovskyte, karolina@caszyme.com
Media: Richard Hayhurst richard@rhacomms.eu